<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653315</url>
  </required_header>
  <id_info>
    <org_study_id>AAI-US-121</org_study_id>
    <nct_id>NCT00653315</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions</brief_title>
  <official_title>To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AAI Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability of Kali and Ortho-McNeil's
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with
      Ortho-McNeil's Ultracet tablets 37.5mg/325mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received kali product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Ortho-Mcneil product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol APAP</intervention_name>
    <description>Tablets, 37.5mg/325mg, single dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ultracet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultracet</intervention_name>
    <description>Tablets, 37.5mg/325mg</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Tramadol APAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Males and females between 18 and 45 years of age inclusive

          -  Informed of the nature of the study and given written informed consent.

          -  Have a body weight within 15% of the appropriate range as defined in the 1983
             Metropolitan Life Company tables and weighing at least 100lbs.

        Exclusion Criteria:

          -  Hypersensitivity to Tramadol/ Acetaminophen, opioids such as morphine and codeine, or
             related compounds, or a history or seizures.

          -  Any history of a clinical condition which might affect drug absorption, metabolism or
             excretion.

          -  Recent history (within one year) of mental illness, drug illness, drug abuse or
             alcoholism.

          -  Donation of greater than 500mL of blood in the past 4 weeks prior to study dosing or
             difficulty in donating blood.

          -  Received an investigational drug within the 4 weeks prior to study dosing.

          -  Currently taking any prescription medication, except oral contraceptives, within 7days
             prior to study dosing or over-the-counter medication within 3 days of the study
             dosing.

          -  This prohibition does not include vitamins or herbal preparations taken as nutritional
             supplements for non-therapeutic indications as judged by the physician.

          -  Tobacco use(&gt;5 cigarettes per day)in the 3 months prior to study dosing.

          -  If female, the subject is lactating or has a positive pregnancy test at screening and
             prior to each of the two treatment periods.

          -  Females of child bearing potential must use a medically acceptable method of
             contraception throughout the entire study period and for one week after the study is
             completed.

          -  Medically acceptable methods of contraception that may be used by the subject and/or
             her partner are:oral contraceptive, progestin injection or implants, condom with
             spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical
             sterilization of their partner(s) or abstinence.

          -  females taking oral contraceptives must have taken them consistently for at least
             three months prior to receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Scallion</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI Clinic</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 9, 2008</last_update_submitted>
  <last_update_submitted_qc>April 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin// Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence, Tramadol APAP, fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

